



For Immediate Release

OMNIA BIOLOGICS EXPANDS ON DRUG DEVELOPMENT COST-MANAGEMENT SERVICES

(April 8, 2009 – Rockville, MD) – Omnia Biologics, Inc. announced today that the Company is further strengthening its service offerings by expanding process development capabilities for companies undertaking cost-cutting measures to preserve capital.

“Omnia understands that much of the overhead associated with drug development requires the application of assets having high fixed and overhead costs,” said Dale VanderPutten, Ph.D., Chief Executive Officer of Omnia. “We have built our business model recognizing these costs are a strain for many firms. Outsourcing non-core activities reduces the risk drug developers face while allowing them to manage cash, contain costs, focus on core strengths, maintain flexibility, and still make progress on pipelines.”

Included in this service expansion has been the hiring of new expertise for early stage vaccine programs and an internal realignment of project management focus to address this market area. Omnia has recently expanded their process development capabilities to include bacterial recombinant protein production and phage particles in addition to their current vaccine and gene therapy capabilities.

“The needs of preclinical vs. Phase II programs are completely different,” states Chad Michalski, Ph.D., Head of Preclinical Development. “One may think he needs to address only one portion of a production process. However, usually this single point results from a series of other process problems and has macro effects on the process. We take a more holistic view of the process to see where specific improvements maybe made outside of the identifiable challenge. We liken this to curing the patient and not the disease.”

“At Omnia we recognize that effective cost management is critical to advancing product development,” continues Dr. VanderPutten. “Working closely with client’s senior management having direct fiscal responsibility allows us to effectively use value-based pricing metrics rather than industry averages. Our clients are pleasantly surprised that we take this approach. Value-based pricing is now more than ever critical to managing constrained resources.”

About Omnia Biologics

Omnia offers contract services for biotechnology and pharmaceutical companies in process development, GMP manufacture, and fill finish for preclinical and Phase I clinical programs of novel therapeutics having significant manufacturing challenges. These products include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.

CONTACT:

Sami Cardak

Director of Manufacturing Services

(301) 984-5928

scardak@omniabio.com